Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

HIV Viral Load Monitoring in Resource-Poor Settings

This study has been completed.
Adult AIDS Clinical Trials Group
Information provided by (Responsible Party):
University of Alabama at Birmingham Identifier:
First received: June 25, 2009
Last updated: October 8, 2014
Last verified: October 2014

No randomized clinical trial to date has demonstrated a survival benefit of using regular HIV-1 ribonucleic acid (RNA) viral load (VL) testing to monitor patients' responses to antiretroviral therapy (ART) for HIV infection. The measurement of VL is recommended to monitor the response to ART in developed countries. In resource-constrained settings, the World Health Organization (WHO) does not recommend routine VL testing, in part due to the cost and complex infrastructure needed for reliable results. In these settings, WHO has proposed the use of clinical and CD4+ lymphocyte-based criteria to guide treatment decisions. However, multiple studies have demonstrated the poor performance of these criteria in sub-Saharan Africa and the frequent discordance between immunologic and virologic responses to ART.

The use of routine viral load monitoring should be evaluated in resource-constrained settings. The investigators hypothesize that routine viral load testing of patients on ART will improve patient survival, decrease disease progression and development of drug resistance, and will be feasible and cost-effective for resource-constrained settings.

Condition Intervention
HIV Infections
Other: HIV-1 viral load testing

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Effectiveness of HIV Viral Load Monitoring of Patient Outcome in Resource-Poor Settings

Resource links provided by NLM:

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • Patient survival [ Time Frame: 36 months ]

Secondary Outcome Measures:
  • To assess HIV clinical disease progression (weight, CD4 cell response, incident opportunistic infections) [ Time Frame: 36 months ]
  • To assess the impact of more rapid ART regimen switching on available second and third-line treatment options [ Time Frame: 36 months ]
  • To monitor the effectiveness of newer antiretroviral medications introduced in Zambia (principally tenofovir) [ Time Frame: 36 months ]
  • To characterize the timing and sequence of HIV drug resistance development among patients in each study arm [ Time Frame: 36 months ]
  • To assess the feasibility, acceptability, and cost effectiveness of the two management strategies in a resource-constrained sub-Saharan African setting [ Time Frame: 36 months ]

Enrollment: 2112
Study Start Date: December 2006
Study Completion Date: June 2014
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Standard of care
Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
Experimental: Routine HIV-1 viral load testing
Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
Other: HIV-1 viral load testing
Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
Other Name: Viral load measured by the Roche Amplicor HIV-1 RNA Monitor kit (version 1.5; Roche Molecular Diagnostics, Pleasanton, CA, USA).

Detailed Description:
The study 'Effectiveness of HIV Viral Load Monitoring on Patient Outcome in Resource-Poor Settings,' is a dual-arm, cluster randomized trial to evaluate the use of routine plasma HIV-1 VL monitoring to improve survival and decrease HIV disease progression in patients receiving ART. The primary objective is to assess mortality at 36 months among ART naïve patients initiating therapy and receiving care at facilities with access to routine HIV VL testing (at ART initiation, at 3 months and at every 6 months thereafter) compared to those initiating first regimens and receiving care at facilities according to our local standard of care (which uses immunological [i.e. CD4+ lymphocyte count-based]and clinical criteria to diagnose treatment failure, with discretionary VL testing when the two do not agree).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented HIV-1 infection (according to local standard rapid testing algorithms)
  • Age 18 years or greater
  • Able and willing to provide informed consent to participate
  • Eligible for antiretroviral therapy per Zambian national guidelines, which are any of the following:

    • CD4+ cell count less than 200 cells/mm3;
    • WHO Stage IV disease; or
    • WHO Stage III disease and CD4+ cell count less than 350 cells/mm3
  • Residence in the geographical catchment area of the VLS clinic and intent to remain there for the duration of the study
  • Willingness to adhere to the study visit schedule and to be followed-up at home in the event of a missed study visit
  • Initiating ART on the day of VLS enrollment, informed consent, and baseline blood collection

Exclusion Criteria:

  • Receipt of more than 7 days (cumulative) of prior antiretroviral therapy at any time prior to study entry, with the exception of zidovudine and/or single dose nevirapine for prevention of mother-to-child transmission;
  • Any exposure to antiretroviral therapy in the past one month
  • A condition that, in the opinion of the investigators, would interfere with adherence to study requirements (e.g., mental illness or active drug or alcohol use or dependence)
  • Serious illness requiring referral to hospital at the time of ART initiation
  • For patients seeking care at sites randomized to the standard of care arm: participation in another research protocol that offers routine viral load testing
  • Unwillingness to consent to all aspects of study protocol including blood specimen storage
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00929604

Centre for Infectious Disease Research in Zambia
Lusaka, Zambia
Sponsors and Collaborators
University of Alabama at Birmingham
Adult AIDS Clinical Trials Group
Principal Investigator: Michael S. Saag, M.D. University of Alabama at Birmingham
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Alabama at Birmingham Identifier: NCT00929604     History of Changes
Other Study ID Numbers: VLS
Study First Received: June 25, 2009
Last Updated: October 8, 2014

Keywords provided by University of Alabama at Birmingham:
viral load
antiretroviral therapy
cluster randomization
ART monitoring
treatment failure
randomized clinical trial
treatment naive

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on April 28, 2017